ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,941 to 1,960 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
VAX-MOM COVID-19 Intervention vs Standard of Care: Rate of COVID-19 Vaccination (6 Month)251 of 2,789

130 of 1,759

1.6 points

-0.0 to 3.2

4,548NCT05570630

VAX-MOM COVID-19: Increasing Maternal COVID-19 Vaccination

Treatment - Participation in Nurse Family Partnership Nurse-Family Partnership vs Control: Number of Participants With a NICU Admission of at Least Overnight241 of 3,046

128 of 1,497

-0.6 points

-2.4 to 1.0

4,543NCT03360539

Nurse-Family Partnership Impact Evaluation in South Carolina

3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Iron Therapy116 of 2,265

122 of 2,269

-0.3 points

-1.6 to 1.0

4,534NCT03252249

Duration of Dual Anti-Platelet Therapy (DUAL-ACS)

Treatment - Participation in Nurse Family Partnership vs Control: Number of Participants Who Received a Gestational Diabetes Test (24-28 Weeks)1,747 of 3,028

869 of 1,502

-0.2 points

-3.2 to 2.9

4,530NCT03360539

Nurse-Family Partnership Impact Evaluation in South Carolina

Drug-specific Alert vs Usual Care: Percentage of Patients With AKI Progression From Stage 1 to Stage 2242 of 2,279

248 of 2,248

-0.4 points

-2.2 to 1.4

4,527NCT02771977

Drug-Targeted Alerts for Acute Kidney Injury

QIVc (≥2 Years to <18 Years of Age) vs Non-Influenza Comparator Vaccine: deaths from any cause0 of 2,258

1 of 2,255

-0.0 points

-0.3 to 0.1

4,513NCT03165617

Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age

QIVc (≥2 Years to <18 Years of Age) vs Non-Influenza Comparator Vaccine: serious adverse events25 of 2,258

30 of 2,255

-0.2 points

-0.9 to 0.4

4,513NCT03165617

Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age

RotaTeq™ vs Placebo: Occurrence of Rotavirus Disease Caused by Serotypes G1, G2, G3 and G4 That Occurs 14 Days Following the 3rd Vaccination82 of 2,207

315 of 2,305

-10.0 points

-11.6 to -8.3

4,512NCT00090233

Rotavirus Efficacy and Safety Trial (REST)(V260-006)

Pregnant Women/Mothers Group vs Neonates/Infants Group: deaths from any cause1 of 2,311

23 of 2,181

-1.0 points

-1.5 to -0.6

4,492NCT03614676

A Study of Outcomes and Events of Interest in Pregnant Women, Neonates and Infants and of RSV Surveillance

Randomization Period: Exemestane vs Randomization Period: Placebo: Incidence of All Clinical Fractures149 of 2,240

143 of 2,248

0.3 points

-1.2 to 1.7

4,488NCT00083174

Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer

Randomization Period: Exemestane vs Randomization Period: Placebo: Incidences of Other Malignancies50 of 2,240

42 of 2,248

0.4 points

-0.5 to 1.2

4,488NCT00083174

Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer

Randomization Period: Exemestane vs Randomization Period: Placebo: Incidence of Clinically Relevant Cardiac Events106 of 2,240

111 of 2,248

-0.2 points

-1.5 to 1.1

4,488NCT00083174

Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer

IDTFK Group Pre-NIPT (January 2010-July 2010) vs IDTFK Group Post NIPT - (January 2012-June 2014): Number of Patient Undergoing IDTFK Before (Control) and After (Test) NIPT Testing Came to Market1,414 of 1,414

3,074 of 3,074

0.0 points

-0.3 to 0.1

4,488NCT02284399

National Prevalence and Impact of Noninvasive Prenatal Testing

IDTFK Group Post NIPT - (January 2012-June 2014) vs IDTFK Group Pre-NIPT (January 2010-July 2010): Frequency of Positive Tests for Abnormal Karyotype Before and After the Adoption of NIPT Testing.454 of 3,074

104 of 1,414

7.4 points

5.5 to 9.2

4,488NCT02284399

National Prevalence and Impact of Noninvasive Prenatal Testing

Colchicine vs Placebo: Number of Participants Who Required Mechanical Ventilation in the 30 Days Following Randomization.11 of 2,235

21 of 2,253

-0.4 points

-1.0 to 0.1

4,488NCT04322682

Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)

Colchicine vs Placebo: Number of Deaths in the 30 Days Following Randomization.5 of 2,235

9 of 2,253

-0.2 points

-0.6 to 0.2

4,488NCT04322682

Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)

Colchicine vs Placebo: Number of Participants Who Died or Were Hospitalized Due to COVID-19 Infection in the 30 Days Following Randomization.104 of 2,235

131 of 2,253

-1.2 points

-2.5 to 0.1

4,488NCT04322682

Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)

Colchicine vs Placebo: Number of Participants Who Were Hospitalized Due to COVID-19 Infection in the 30 Days Following Randomization.101 of 2,235

128 of 2,253

-1.2 points

-2.5 to 0.1

4,488NCT04322682

Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)

Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs)20 of 2,238

81 of 2,246

-2.7 points

-3.6 to -1.9

4,484NCT00141102

Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis

Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With Moderate to Severe Abdominal Symptoms132 of 2,238

162 of 2,246

-1.3 points

-2.8 to 0.1

4,484NCT00141102

Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=98"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=98

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT05570630-704e061d",
        "title": "VAX-MOM COVID-19 Intervention vs Standard of Care: Rate of COVID-19 Vaccination (6 Month)",
        "summary": "251 of 2789 against 130 of 1759; risk difference 1.6 points, 95% interval -0.0 to 3.2; NCT05570630, VAX-MOM COVID-19: Increasing Maternal COVID-19 Vaccination",
        "record": "/library/comparisons/NCT05570630-704e061d",
        "nct_id": "NCT05570630",
        "kind": "outcome",
        "participants": 4548,
        "risk_difference": {
          "value": 0.016090786287638992,
          "lower": -0.0004896596988651185,
          "upper": 0.03200925260482681
        },
        "group_1": "251 of 2,789",
        "group_2": "130 of 1,759",
        "difference": "1.6 points",
        "interval": "-0.0 to 3.2",
        "trial_title": "VAX-MOM COVID-19: Increasing Maternal COVID-19 Vaccination"
      },
      {
        "id": "NCT03360539-3d4873ae",
        "title": "Treatment - Participation in Nurse Family Partnership Nurse-Family Partnership vs Control: Number of Participants With a NICU Admission of at Least Overnight",
        "summary": "241 of 3046 against 128 of 1497; risk difference -0.6 points, 95% interval -2.4 to 1.0; NCT03360539, Nurse-Family Partnership Impact Evaluation in South Carolina",
        "record": "/library/comparisons/NCT03360539-3d4873ae",
        "nct_id": "NCT03360539",
        "kind": "outcome",
        "participants": 4543,
        "risk_difference": {
          "value": -0.006384184433651727,
          "lower": -0.02412264999152204,
          "upper": 0.010192731630365222
        },
        "group_1": "241 of 3,046",
        "group_2": "128 of 1,497",
        "difference": "-0.6 points",
        "interval": "-2.4 to 1.0",
        "trial_title": "Nurse-Family Partnership Impact Evaluation in South Carolina"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=99",
  "request_id": "IsljZsTIfrorIMLp"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?